Iodine-125 implants for carcinoma of the prostate

Peschel, Richard E.; Fogel, Thomas D.; Kacinski, Barry M.; Kelly, Kathleen A.; Mate, Timothy P.

doi:10.1016/0360-3016(85)90031-8

Cited by 33 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Follow‐up, however, disclosed a high rate of local failure with the iodine‐125 implant. Advances in external beam radiation and radical prostatectomy techniques of that time period eventually led to a waning of interest in brachytherapy as a treatment for prostate carcinoma 2‐16…”

mentioning

confidence: 99%

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Ragde

Blasko

Grimm

et al. 1997

Cancer

246

View full text Add to dashboard Cite

William Cavanagh, B.S. 3 Posttherapy evaluation included clinical, biochemical (PSA), and pathologic (repeat needle biopsy) studies. No patient was surgically staged, and none received andro-1 Pacific Northwest Cancer Foundation/Northgen deprivation therapy. Morbidity was graded according to the Radiation Therapy west Hospital, Seattle, Washington.Oncology Group grading scale. Statistical appraisal was performed by the Kaplan-2 Department of Urology, University of WashMeier method. PSA failure was defined in two ways: (1) PSA progression, i.e., 2 ington, Seattle, Washington.consecutive increases from a nadir value; and (2) failure to attain an arbitrary serum PSA value of 1.0 or 0.5 ng/mL at last follow-up. 3 Department of Radiation Oncology, University RESULTS. The overall 7-year survival was 77%; there were no deaths from prostate of Washington, Seattle, Washington.carcinoma in this cohort. The 7-year actuarial PSA progression free outcome was 4 Northwest Tumor Institute, Seattle, Washing-89%, and the PSA°1.0 ng/mL outcome was 87%. When PSA°0.5 ng/mL was ton.selected as an outcome end point, and PSA values in this series of radiation-treated 5 Pathology Associates Inc., Spokane, Washingpatients were compared with PSA values proposed to indicate disease free survival ton.after radical prostatectomy (PSA°0.3-°0.6 ng/mL), the 7-year actuarial disease free survival was 79%. Morbidity was minimal except in patients who had preimplant or postimplant transurethral prostate resection. CONCLUSIONS.Outpatient-based iodine-125 prostate brachytherapy for prostate carcinoma classified as T1 or T2 resulted in biochemical outcomes comparable to end points resulting from radical prostatectomy and external beam radiation.

show abstract

mentioning

confidence: 99%

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Ragde

Blasko

Grimm

et al. 1997

Cancer

246

View full text Add to dashboard Cite

show abstract

“…The treatment of low-and intermediate-risk prostate cancer with permanent seed brachytherapy implant (Blasko et al 1993, Peschel et al 1985, Nag et al 1999 is recognized as a potential technique that provides an alternative to radical surgery or external beam radiation therapy (Kupelian et al 2004, Potters et al 2004. In selected patients, brachytherapy with seed implants provides tumor control as high as surgical prostactomy or external beam radiotherapy, while maintaining lower rate of complications (Blasko et al 1993, Davis et al 2001.…”

Section: Introductionmentioning

confidence: 99%

A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy

Ali

Algan²,

Thompson³

et al. 2009

Phys. Med. Biol.

View full text Add to dashboard Cite

This work investigates variation in the volume of the prostate measured at different stages through the prostate brachytherapy procedure for 30 patients treated with I-125 radioactive seeds. The implanted seeds were localized on post-implantation ultrasound (US) images and the effect of prostate enlargement due to edema on dose coverage for 15 patients was studied. The volume of the prostate was measured at four stages as follows: (a) 2-3 weeks prior to implantation using US imaging, (b) then at the start of the intra-operative prostate brachytherapy procedure on the day of the implant, (c) immediately post-implantation using US imaging in the operating room and (d) finally by CT imaging at nearly 4 weeks post-implantation. Comparative prostate volume studies were performed using US imaging stepper and twister modes. For the purpose of this study, the implanted seeds were localized successfully on post-implant ultrasound twister images, retrospectively. The plans using post-implant US imaging were compared with intra-operative plans on US and plans created on CT images. The prostate volume increases about 10 cm(3) on average due to edema induced by needle insertion and seed loading during implantation. The visibility of the implanted seeds on US twister images acquired post-implantation is as good as those on CT images and can be localized and used for dose calculation. The dose coverage represented by parameters such as D90 (dose covering 90% of the volume) and V100 (volume covered by 100% dose) is poorer on plans performed on post-implantation twister US studies than on the intra-operative live plan or the CT scan performed 4 weeks post-operatively. For example, the mean D90 difference on post-implantation US is lower by more than 15% than that on pre-implantation US. The volume enlargement of the prostate due to edema induced by needle insertion and seed placement has a significant effect on the quality of dosimetric coverage in brachytherapy prostate seed implants. Here, we introduced a new approach based on the use of post-implant US twister images to correct for prostate enlargement intra-operatively. Besides the ability to localize the seeds and superior soft tissue visibility, the twister US images include effects of the enlargement of the prostate gland and seed migration during the implantation procedure.

show abstract

An early Phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases

Firusian¹,

Dempke

1999

Cancer

View full text Add to dashboard Cite

Iodine-125 implants for carcinoma of the prostate

Cited by 33 publications

References 9 publications

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy

An early Phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases

Contact Info

Product

Resources

About